🎉 M&A multiples are live!
Check it out!

Lisata Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Lisata Therapeutics and similar public comparables like Vivoryon Therapeutics, Julphar, and Benevolent AI.

Lisata Therapeutics Overview

About Lisata Therapeutics

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.


Founded

1980

HQ

United States of America
Employees

26

Website

lisata.com

Financials

LTM Revenue $0.7M

LTM EBITDA -$23.1M

EV

-$14.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Lisata Therapeutics Financials

Lisata Therapeutics has a last 12-month revenue of $0.7M and a last 12-month EBITDA of -$23.1M.

In the most recent fiscal year, Lisata Therapeutics achieved revenue of $1.0M and an EBITDA of -$22.2M.

Lisata Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Lisata Therapeutics valuation multiples based on analyst estimates

Lisata Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $1.0M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$25.5M -$22.2M XXX XXX XXX
EBITDA Margin -Infinity% -2223% XXX XXX XXX
Net Profit -$54.2M -$20.8M XXX XXX XXX
Net Margin -Infinity% -2084% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Lisata Therapeutics Stock Performance

As of April 15, 2025, Lisata Therapeutics's stock price is $2.

Lisata Therapeutics has current market cap of $16.9M, and EV of -$14.2M.

See Lisata Therapeutics trading valuation data

Lisata Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$14.2M $16.9M XXX XXX XXX XXX $-2.39

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Lisata Therapeutics Valuation Multiples

As of April 15, 2025, Lisata Therapeutics has market cap of $16.9M and EV of -$14.2M.

Lisata Therapeutics's trades at -20.0x LTM EV/Revenue multiple, and 0.6x LTM EBITDA.

Analysts estimate Lisata Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Lisata Therapeutics and 10K+ public comps

Lisata Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$14.2M XXX XXX XXX
EV/Revenue -14.2x XXX XXX XXX
EV/EBITDA 0.6x XXX XXX XXX
P/E -0.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Lisata Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Lisata Therapeutics Valuation Multiples

Lisata Therapeutics's NTM/LTM revenue growth is -100%

Lisata Therapeutics's revenue per employee for the last fiscal year averaged $38K, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Lisata Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Lisata Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Lisata Therapeutics and other 10K+ public comps

Lisata Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -2223% XXX XXX XXX XXX
EBITDA Growth -13% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee $38K XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 1208% XXX XXX XXX XXX
R&D Expenses to Revenue 1133% XXX XXX XXX XXX
Opex to Revenue 2341% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Lisata Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Lisata Therapeutics M&A and Investment Activity

Lisata Therapeutics acquired  XXX companies to date.

Last acquisition by Lisata Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Lisata Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Lisata Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Lisata Therapeutics

When was Lisata Therapeutics founded? Lisata Therapeutics was founded in 1980.
Where is Lisata Therapeutics headquartered? Lisata Therapeutics is headquartered in United States of America.
How many employees does Lisata Therapeutics have? As of today, Lisata Therapeutics has 26 employees.
Who is the CEO of Lisata Therapeutics? Lisata Therapeutics's CEO is Dr. David J. Mazzo, PhD.
Is Lisata Therapeutics publicy listed? Yes, Lisata Therapeutics is a public company listed on NAS.
What is the stock symbol of Lisata Therapeutics? Lisata Therapeutics trades under LSTA ticker.
When did Lisata Therapeutics go public? Lisata Therapeutics went public in 1999.
Who are competitors of Lisata Therapeutics? Similar companies to Lisata Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Lisata Therapeutics? Lisata Therapeutics's current market cap is $16.9M
What is the current revenue of Lisata Therapeutics? Lisata Therapeutics's last 12-month revenue is $0.7M.
What is the current EBITDA of Lisata Therapeutics? Lisata Therapeutics's last 12-month EBITDA is -$23.1M.
What is the current EV/Revenue multiple of Lisata Therapeutics? Current revenue multiple of Lisata Therapeutics is -20.0x.
What is the current EV/EBITDA multiple of Lisata Therapeutics? Current EBITDA multiple of Lisata Therapeutics is 0.6x.
Is Lisata Therapeutics profitable? Yes, Lisata Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.